Acute myocardial infarction (AMI) is a life-threatening event. Even with timely treatment, acute ischemic myocardial injury and ensuing ischemia reperfusion injury (IRI) can still be difficult issues to tackle. Apart from radiological and other auxiliary examinations, laboratory tests of applicable cardiac biomarkers are also necessary for early diagnosis and close monitoring of this disorder. Heart-type fatty acid binding protein (H-FABP), which mainly exists inside cardiomyocytes, has recently emerged as a potentially promising biomarker for myocardial injury. In this review we discuss the sensitivity and specificity of H-FABP in the assessment of myocardial injury and IRI, especially in the early stage, and its long-term prognostic value in comparison with other commonly used cardiac biomarkers, including myoglobin (Mb), cardiac troponin I (cTnI), creatine kinase MB (CK-MB), C-reactive protein (CRP), glycogen phosphorylase isoenzyme BB (GPBB), and high-sensitivity cardiac troponin T (hs-cTnT). The potential and value of combined application of H-FABP with other biomarkers are also discussed. Finally, the prospect of H-FABP is summarized; several technical issues are discussed to facilitate wider application of H-FABP in clinical practice.

中文翻译：

---

心脏型脂肪酸结合蛋白（H-FABP）作为急性心肌损伤和长期缺血后预后的生物标志物。

急性心肌梗塞（AMI）是威胁生命的事件。即使及时治疗，急性缺血性心肌损伤和随后的局部缺血再灌注损伤（IRI）仍然是难以解决的问题。除了放射学检查和其他辅助检查之外，对于这种疾病的早期诊断和密切监测，还需要对适用的心脏生物标志物进行实验室检查。心脏型脂肪酸结合蛋白（H-FABP）主要存在于心肌细胞中，最近已成为潜在的有希望的心肌损伤生物标志物。在这篇综述中，我们讨论了H-FABP在评估心肌损伤和IRI（尤其是早期阶段）方面的敏感性和特异性，以及与其他常用的心脏生物标记物（包括肌红蛋白（Mb））相比的长期预后价值，心肌肌钙蛋白I（cTnI），肌酸激酶MB（CK-MB），C反应蛋白（CRP），糖原磷酸化酶同工酶BB（GPBB）和高敏感性心肌肌钙蛋白T（hs-cTnT）。还讨论了将H-FABP与其他生物标志物联合应用的潜力和价值。最后总结了H-FABP的前景。讨论了一些技术问题，以促进H-FABP在临床实践中的广泛应用。